Agilent Unveils BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Introduces the BioTek Cytation 9 Cell Imaging Multimode Reader Agilent Technologies, Inc. has announced the launch of its latest innovation in laboratory instrumentation, the BioTek Cytation 9 cell imaging…
Janux Therapeutics Names New Candidate in Bristol Myers Squibb Collaboration, Triggers $35M Milestone
Janux Therapeutics Confirms Candidate Nomination in Bristol Myers Squibb Partnership, Activating $35 Million Milestone Payment Janux Therapeutics, Inc. has announced a significant milestone under its strategic collaboration with Bristol Myers…
Thermo Fisher Scientific Unveils Integrated Platform to Streamline and Accelerate Biologics Development
Thermo Fisher Scientific Introduces Unified Platform to Speed Biologics Development Thermo Fisher Scientific Inc., a global leader in scientific services and life sciences solutions, has introduced a next-generation, integrated cell…
RefleXion Gains Expanded Medicare Reimbursement Coverage for SCINTIX Cancer Therapy
RefleXion Achieves Broader Medicare Reimbursement Approval for SCINTIX Cancer Therapy RefleXion Medical has announced a significant advancement in reimbursement support for its innovative SCINTIX® autonomous radiotherapy platform, as Noridian Healthcare…
Gilead Prolongs Tender Offer Period for Acquisition of Arcellx
Gilead Extends Tender Offer Timeline for Planned Acquisition of Arcellx Gilead Sciences, Inc. has announced an extension of its ongoing tender offer to acquire all outstanding shares of common stock…
Alto Neuroscience Announces Topline Phase 2 Proof-of-Concept Results for ALTO-101 and Showcases Pipeline Progress
Alto Neuroscience Shares Topline Results from Phase 2 Proof-of-Concept Trial of ALTO-101 and Highlights Ongoing Pipeline Progress Alto Neuroscience, Inc. has announced topline results from its Phase 2 proof-of-concept (POC)…
FORE Biotherapeutics Granted Breakthrough Therapy Designation for Plixorafenib
FORE Biotherapeutics Earns Breakthrough Therapy Designation for Plixorafenib FORE Biotherapeutics, a registration-stage biopharmaceutical company focused on developing precision therapies for cancer, has announced a significant regulatory milestone for its lead…
Shionogi Finalizes Full Acquisition of Global Rights to RADICAVA (Edaravone)
Shionogi Secures Complete Ownership of Global Rights to RADICAVA (edaravone) Shionogi & Co., Ltd. has announced the successful completion of a major strategic transaction involving the full transfer of rights…
VDYNE Secures FDA Approval to Launch TRIVITA1 IDE Pivotal Trial for Transcatheter Tricuspid Valve Replacement System
VDYNE Secures FDA IDE Clearance to Launch TRIVITA1 Pivotal Trial for Its Transcatheter Tricuspid Valve Replacement System VDYNE, Inc., a privately held medical device innovator focused on advancing next-generation structural…
Agenus Begins Phase 3 BATTMAN Trial of BOT+BAL Combo in Metastatic Colorectal Cancer
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial Evaluating BOT+BAL Combination in MSS/pMMR Metastatic Colorectal Cance Agenus Inc., a clinical-stage immuno-oncology company focused on developing novel therapies…
Biogen to Acquire Apellis, Expanding Immunology and Rare Disease Portfolio and Entering Nephrology
Biogen’s Acquisition of Apellis Strengthens Immunology and Rare Disease Portfolio While Accelerating Growth and Entry into Nephrology Biogen Inc. and Apellis Pharmaceuticals (Nasdaq: APLS) have announced a definitive agreement under…
Bristol Myers Squibb Marks a Decade of GAAP Progress, Expanding Efforts to Advance Equity in Multiple Myeloma Care
Bristol Myers Squibb Strengthens and Expands Commitment to Advancing Equitable Care in Multiple Myeloma as GAAP Initiative Reaches Ten Years Bristol Myers Squibb (NYSE: BMY), a recognized leader in oncology,…